Evidence map›Paper›PMID 42388375›Full record

ArticleMaterials today. Bio2026

Membrane-camouflaged metal-phenolic nanomedicines for the treatment of ischemic stroke via relieving oxidative stress and neuroinflammation.

Bingyuan Liu, Xinyi Chen, Luyun Tu, Lixin Yin, Hongxia Huang, Ye Wu, Hui Cai, Yiliang Li, Sheng Hong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Bingyuan LiuSchool of Pharmaceutical Sciences (Shenzhen), State Key Laboratory of Anti-Infective Drug Discovery and Development, Shenzhen Campus of Sun Yat-sen University, Shenzhen, 518107, PR China.
Xinyi ChenDepartment of Rehabilitation, Renmin Hospital of Wuhan University, Wuhan, 430060, PR China.
Luyun TuSchool of Pharmaceutical Sciences (Shenzhen), State Key Laboratory of Anti-Infective Drug Discovery and Development, Shenzhen Campus of Sun Yat-sen University, Shenzhen, 518107, PR China.
Lixin YinSchool of Pharmaceutical Sciences (Shenzhen), State Key Laboratory of Anti-Infective Drug Discovery and Development, Shenzhen Campus of Sun Yat-sen University, Shenzhen, 518107, PR China.
Hongxia HuangSchool of Pharmaceutical Sciences (Shenzhen), State Key Laboratory of Anti-Infective Drug Discovery and Development, Shenzhen Campus of Sun Yat-sen University, Shenzhen, 518107, PR China.
Ye WuSchool of Pharmaceutical Sciences (Shenzhen), State Key Laboratory of Anti-Infective Drug Discovery and Development, Shenzhen Campus of Sun Yat-sen University, Shenzhen, 518107, PR China.
Hui CaiSchool of Pharmaceutical Sciences (Shenzhen), State Key Laboratory of Anti-Infective Drug Discovery and Development, Shenzhen Campus of Sun Yat-sen University, Shenzhen, 518107, PR China.
Yiliang LiDepartment of Rehabilitation, Renmin Hospital of Wuhan University, Wuhan, 430060, PR China.
Sheng HongSchool of Pharmaceutical Sciences (Shenzhen), State Key Laboratory of Anti-Infective Drug Discovery and Development, Shenzhen Campus of Sun Yat-sen University, Shenzhen, 518107, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ischemia-reperfusion injury (IRI) following thrombolytic therapy significantly influences the ischemic stroke outcomes. Here, we develop M@EFE NPs, a biomimetic nanomedicine, to alleviate the reperfusion injury. This nanomedicine is constructed by encapsulating Edaravone into the metal-phenolic nanoparticles self-assembled from epigallocatechin gallate (EGCG) and iron ions (Fe

Indexed as

AntioxidantEdaravoneEGCG-Fe3+ nanoparticlesIschemia-reperfusion injuryMacrophage membraneNeuroprotection

Identifiers

PMID42388375
PMCPMC13320281

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.